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In vivo, the glucocorticoid steroids inhibit fibroblast 
growth and the production of specific cell products such 
as collagen and mucopolysaccharide. Depending on the 
source of the fibroblasts and their growth conditions, 
several responses can be observed in cultured cells; the 
proliferation of L cells is inhibited, the growth of syn-
ovial fibroblasts is usually stimulated, and some cultured 
fibroblasts do not respond. The inhibition of L cell 
growth is preceded by alterations in the rates of hexo~e 
and amino acid transport. As in other cell types, there IS 
evidence that the effects of glucocorticoids in fibroblasts 
are mediated via the induction of new protein synthesis. 
The specifi~ induced proteins responsible for inhibiting 
the growth of mouse L929 fibroblasts (or any other cell 
type) have not been identified. It is possible that gluco-
corticoids induce the synthesis of a few proteins that, by 
virtue of their ability to modify (either during or after 
translation) other proteins involved in several key cel-
lular events, are able to compromise multiple systems 
and produce growth inhibition. Glucocorticoid-mediated 
alteration of protein phosphorylation could account for 
the pleiotropic nature of the hormone effect. 
To cause a glucocorticoid-specific response in the cell, 
these hormones must first bind to a cellular receptor. A 
significant amount of evidence suggests (a) that gluco-
corticoid receptors may undergo an energy-dependent 
cycling in the cell and (b) that a single receptor may ~e 
able to participate several times in the process of sterOId 
binding and gene activation. Maximal physiological re-
sponse to, and consequently the clinical response 
achieved with, a glucocorticoid is usually a function of 
the extent to which the hormone can be bound in a 
specific manner. Investigators have proposed that the 
specific glucocorticoid-binding capacity of a cell is deter-
mined by a phosphorylation-dephosphorylation mecha-
nism. 
Glucocorticoids differ from other steroid hormones in that 
they produce effects in almost all tissues and cell types. The 
nature of the physiological response varies according to the cell 
or system being examined. Munck and Leung in. an excell:nt 
comprehensive review [1] have recently summanzed the wlde 
variety of physiological and biochemical effects produced by 
glucocorticoids. In general, the physiological effects of gluco-
corticoids in fibroblasts are antianabolic. That is, these drugs 
inhibit growth and the production of important cell products 
such as collagen [2] and mucopolysaccharide [3]. Even within 
the 1 cell type, however, the physiological response is not 
constant. The growth rate of some fibroblasts maintained in 
culture is actually stimulated by exposure to low concentrations 
of glucocorticoid, and in a few systems no alteration in growth 
rate has been observed. Thus, it is appropriate that I begin this 
discussion with a short review of the effect of glucocorticoids 
on fibroblast growth. 
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Effects of Glucocorticoids on Fibroblast Growth 
Glucocorticoids are capable of inhibiting the processes of 
wound healing and fibrosis. In early efforts to understand the 
profound effects of this class of hormones on conn.ective tiss~e, 
several investigators [4,5] established that systemlcally admm-
istered glucocorticoids can inhibit the growth of .fibroblasts. in 
model would repair systems. Although changes m connectIve , 
tissue were not observed by Baker and Whitaker [6,7] in the 
first studies on glucocorticoid effects after local administration, 
Castor and Baker [8] subsequently demonstrated a considerable 
reduction in the number of dermal fibroblasts in areas of rat 
skin exposed to topically applied drug. Later, it was shown that 
cortisol and other glucocorticoids can inhibit the rate of growth 
of fibroblasts in culture [9], a finding that confirmed earlier 
conclusions that the effect was independent of the actions of 
these hormones on other cell types and on the vasculature . The 
earliest studies showing an inhibition of fibroblast growth in 
vitro employed exceedingly high drug concentrations [10-12] , 
and it was not until the work of Ruhmann and Berliner [13] in 
1965 that an unequivocal demonstration of the growth inhibi-
tory effect was accomplished in a readily manipulated, well-
characterized fibroblast line growing in vitro. These workers 
carried out extensive stereospecificity studies in L 929 mouse 
fibroblasts (this line was originally derived from subcutaneous 
connective tissue of a C3HI An mouse) and demonstrated that 
the activity of steroids in suppressing L cell growth reflects 
their clinical efficacy as anti-inflammatory agents [13,14]. The 
major exceptions are the ll-keto compounds (cortisone, pred-
nisone) that do not inhibit growth in L cells because they are 
not converted to the active ll-hydroxy form [14]. 
In general, steroids inhibit the growth rate of L cells [9,15,16] 
but do not cause the cytolysis that occurs in some cell types 
(e.g. , thymic lymphocytes [17]) . Even after several ~ays of 
constant exposure to maximum inhibitory concentratIons of 
glucocorticoid, growth resumes on withdrawal of the drug 
[16,18]. The major exception to these observations may be the 
work of Rhumann and Berliner [13]; their observation that 
large decreases in cell number occwTed within 3 to 5 days after 
introduction of potent steroids into L cell monolayer cultures 
suggests that considerable cell killing occurred in their experi-
ments. 
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A definite change in cell structure accompanies the steroid 
effect. Steroid-treated L cells are larger, flatter, less densely 
packed, and often more polygonal and epithelial in appearance 
than controls [19,20]. Some investigators have speculated that 
this morphological change may represent a phenotypic rever-
sion from a "transformed, or tumor cell-like state to a more 
tightly regulated growth state" [20] . . . 
Glucocorticoids inhibit DNA synthesis and growth ill pnmary 
chick embryo fibroblast cultures, although they have no effect 
if the cells have been transformed with Rous sarcoma virus 
[21]. Cultured fibroblasts do not always respond to glucocorti-
coids with a negative growth effect. The growth of SM-C1 
fibroblasts (derived from a rat carrageenan granuloma) is not 
altered, although cell functions such as secretion of collagen 
and glycosaminoglycans are markedly decreased [22]. Gluco-
corticoids also inhibit the production of these intercellular 
substances in fibroblasts cultured from human synovial tissue, 
but these cells usually respond with a moderate increase in 
growth rate [2,3,23,24]. Considerable interest has focused on 
the growth-promoting effect of glucocorticoids in 3T3 mouse 
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fibroblasts. The 3T3 lines (derived from disaggregated mouse 
embryos) are density-inhibited cell systems that have been used 
as a model in studies on growth regulation and transformation. 
Thrash and Cunningham observed that the addition of gluco-
corticoid to density-inhibited 3T3 cells was followed by the 
initiation of cell growth [25,26] . The effect is specific for gluco-
corticoids, and the steroids have no effect in polyoma- or SV40-
transformed 3T3 lines. Although it is not clear from this work 
whether the growth stimulation was a direct steroid effect or 
whether the glucocorticoid may have "permitted" the growth-
stimulating action offactors in serum, results from other studies 
strongly suggest the latter mechanism. 
Armelin [27] showed that, although hydrocortisone has no 
growth-promoting effect of its own in 3T3 cultures, growth 
stimulated by pituitary extracts is greatly enhanced by this 
steroid. Using different 3T3 lines, Gospodarowicz and others 
[28-30] confirmed that glucocorticoids alone do not stimulate 
the initiation of DNA synthesis or cell proliferation in 3T3 
cultures, and they showed that the steroids potentiate the effect 
of fibroblast growth factor (FGF). The FGF is a polypeptide 
with a molecular weight of 13,300, that has been purified from 
bovine pituitary gland [31]. In the presence of a low concentra-
tion of dexamethasone, FGF can sustain multiple divisions of 
3T3 fibroblasts in serum-starved cultures (although it should 
be made clear that the FGF effect is not specific for these cells 
or even for fibroblasts since it can act as a mitogen for a variety 
of cell types from murine, bovine and human sources [31]). It 
has been noted that when 3T3 cells are permitted to grow to 
high density by exposure to FGF in the presence of glucocorti-
coid, they assume the appearance of transformed cells [32]. 
When prostaglandin F2n (PGF2n) is added to quiescent 3T3 
fibroblast cultures, DNA synthesis and growth are initiated 
[33]. This stimulation is inhibited by low concentrations of 
glucocorticoids [34]. Thus the same concentrations of hydro-
cortisone can increase the rate of DNA synthesis induced by 
FGF [28,29] and decrease the rate induced by PGF2n in the 
same Swiss mouse 3T3 fibroblast cultures. 
Reports regarding the effect of glucocorticoid 'on human skin 
cells in culture have been somewhat conflicting. Till'ash and 
Cunningham [25] reported that early passage diploid human 
foreskin fibroblasts were stimulated by cortisol. Gospodarowicz 
and Moran [35], however, found no growth stimulation by 
dexamethasone alone and no potentiation of the FGF effect in 
similar cultures. Kamely and Rudland [36] examined 2 cell lines 
obtained from human skin biopsy specimens, and again gluco-
corticoid neither sustained growth nor potentiated the effect of 
FGF. 
Summary. Glucocorticoids administered to animals either system-
ically or topically can depress fibroblast growth and function. A similar 
growth-inhibiting effect occurs in L 929 mouse fibroblasts in culture, 
The relative potencies of steroids in inhibiting L cell growth correlates 
well with their topical anti-inflammatory activity [37]. Several types of 
fibroblasts in culture do not respond to glucocorticoids with a decrease 
in growth rate. In the case of some density-inhibited fibroblasts, the 
glucocorticoids potentiate the effect of polypeptide growth factors but 
they usually do not affect the growth rate when they are present a lone. 
When these cells are transformed, the glucocorticoids no longer affect 
their growth. The growth of fibroblasts cultured from human synovial 
t issue is stimulated, but this effect may reflect an ability of these 
steroids to enhance the growth-promoting effects of serum factors. In 
the remainder of this paper I will review studies on the mechanism of 
action of glucocorticoids in fibroblasts. 
Biochemical Events Inhibited by Glucocorticoids in Mouse 
Fibroblasts 
Initial studies on the biochemical effects of glucocorticoids in 
L cells focused on possible alterations in the rates of protein 
and nucleic acid synthesis. When L cells growing in log phase 
in mor.lOlayer culture were exposed to maximally effective con-
centrations of glucocorticoid (e.g., 5 X 10- 7 M fluocinolone 
acetonide), an inhibition of the rate of incorporation of thymi-
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dine into DNA was evident within about 6 hr [15]. After 24 hr 
of exposure to hormone, incorporation of thymidine was in-
hibited by about 50% and that of uridine by about 25% (Fig 1) . 
Protein synthesis, as estimated by the incorporation of radio-
labeled leucine into the acid-insoluble fraction, was not in-
hibited. Indeed, the incorporation of leucine expressed on a per 
cell basis was minimally stimulated [15]. Seifert and Hilz [16] 
assayed thymidine incorporation rates in suspension cultures of 
L cells over a period of several days of exposure to cortisol. 
Maximum inhibition of thymidine incorporation was about 70% 
and was achieved in 24 hr. Incorporation ofradiolabeled proline 
into cold acid-insoluble material was increased in cells exposed 
to steroid. The observation (made under both culture condi-
tions) that thymidine incorporation was never completely in-
hibited while cell growth was virtually stopped is consistent 
with the fact that DNA content per cell increased about 1.5-
fold in the experiments of Seifert and Hilz [16]. 
Nucleic acid synthesis has also been studied in intact nuclei 
isolated from L cells exposed to fluocinolone acetonide for 12 
hI' prior to harvest [38]. It was demonstrated that incorporation 
of ribo- or deoxyribonucleoside triphosphates into cold acid-
insoluble material by these nuclear preparations is actinomycin-
D-sensitive and requires the presence of all four complementary 
nucleotides. The products of CH]dATP and [3H]ATP incorpo-
ration were chemically identified as DNA and RNA, respec-
tively. The DNA was of low molecular weight and did not 
sediment with bulk DNA in alkaline sucrose gradients. In this 
system, the ability of nuclei from cortisol-treated cells to incot-
pOl'ate nucleoside triphosphates into both DNA and RNA was 
inhibited about 25% relative to controls [38]. Because the 
substrates were provided in the triphosphorylated form, these 
results suggest that within 12 hr the steroid affected compo-
nents of the nucleic-acid-synthesizing systems. Thus, all of the 
inhibition of radiolabeled nucleoside incorporation observed in 
intact cells was probably not due to effects on precursor uptake 
or conversion to triphosphates. 
Inhibition of nucleic acid synthesis is a late effect 6f the 
hormone, and it is not clear from these studies the extent to 
which it contributes to the observed growth inhibition. Prior to 
effects on nucleic acid synthesis, the uptake of hexose and 
amino acids into the cell was inhibited. Co-workers and I 
examined the effect of steroids on the uptake of radiolabeled 
galactose and 2-deoxyglucose in L cells [39]. Galactose is taken 
up by L cells and converted to galactose-I-phosphate and 
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FIG 1. Time course of inhibition of hexose uptake, nucleoside incar-
poration, and growth caused by glucocorticoid in L 929 mouse fibroblast 
cultures (data for galactose uptake taken from Gray, Pratt, and Al'onow 
[39]; data for nucleoside incorporatiol1 a~d growth taken from Pratt 
and Aronow [15]). Galactose uptake was used as a measure of the effect 
of glucocorticoids on the rate of hexose transport. The rates of galactose 
uptake or nucleoside incorporation ru'e expressed as percentages of 
contl'ol rates assayed in untreated cultures. I obtained the curve defin-
ing inhibition of cell growth by counting the number of cells per 
glucocorticoid-treated cultme and expressing this value as a percent of 
the cell count in untreated controls. 
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uridine diphosphogalactose, but these cells lack the enzyme 
uridine diphosphogalactose-4-epimerase [40] and galactose can-
not be utilized as an energy source [41]. Because the uptake 
mechanism for galactose and 2-deoxyglucose, another non-
energy-yielding hexose, is shared with glucose [39], we used 
these compounds to measure hexose uptake and phosphoryla-
tion. (It should be noted, however, that glucose is taken up by 
2 mechanisms in these cells and the one that is apparently not 
shared with galactose could be physiologically more important.) 
When L cells were suspended in an isotonic salt solution in the 
absence of glucose, inhibition of radiolabeled galactose uptake 
was not apparent until 1 to 2 hr after addition of glucocorticoid 
(Fig 1). When glucose was present in the suspension solution, 
inhibition of radiolabeled galactose uptake was observed much 
earlier (within 30 min to 1 hr) . This enhancement of the steroid 
effect by glucose required metabolism. When cells were prein-
cubated for 90 min in the absence of glucose but radio labeled 
galactose uptake was measured in the presence of glucose, the 
steroid-mediated inhibition was the same as in glucose-free 
controls. When glucose was present during the preincubation 
period, however, inhibition of galactose uptake was about 1.7-
fold that observed in control samples. The fact that cells prein-
cubated with glucose were more sensitive to the steroid effect 
than controls incubated in the absence of substrate suggests 
that active cell metabolism is necessary for rapid expression of 
the hormone effect. It was not possible to measure 3-0-meth-
ylglucose uptake rates in L cells, and it was not clearly dem-
onstrated that the inhibition of hexose uptake represented an 
effect on transmembrane passage rather than phosphorylation. 
On the basis of detailed observation of thymic lymphocytes 
in which inhibition of glucose uptake was seen within 15 to 20 
min after addition of glucocorticoid [42,43], Munck suggested 
that the inhibition of glucose uptake is an essential step in the 
catabolic actions of glucocorticoids in these cells [44]. In L cells, 
growth supported by high concentrations of fructose (this hex-
ose is metabolized but it does not interact with the uptake 
processes f.or glucose or galactose) is as sensitive to inhibition 
as growth supported by glucose [39]. This fact argues against 
the proposal that inhibition of hexose transport is absolutely 
necessary for the growth-inhibiting effect of glucocorticoids in 
this system. 
Glucocorticoids have also been shown to inhibit the rate of 
uptake of a -aminosobutyric acid (AlB) in mouse fibroblasts 
[39]. This is an amino acid that is not utilized by L cells but 
that is actively transported into them by a process shared with 
some of the naturally occurring L-amino acids [45]. Inhibition 
of hexose and AID uptake has been demonstrated in prepara-
tions of mouse skin exposed to glucocorticoids in vitro [46-48]. 
As described above, general protein synthesis in L cells is not 
inhibited by glucocorticoids [15], but it is possible that selective 
inhibition of the synthesis of some individual proteins may 
occur, and that this inhibition may be of some consequence to 
the growth-inhibiting effect. P lasminogen activator is a protein 
that may play an important role in permitting rapid growth of 
some cultured cells, and the plasminogen activator activity of 
L cells is markedly decreased on exposure to 10- 7 M dexameth-
asone [20]. Wong and Aronow [49] have recently reported 
selective inhibition of incorporation of radioactive amino acids 
into a ~ysine-rich histone component identified in L cell nuclei. 
It is not clear whether the finding reflects decreased synthesis 
of this protein fraction or some other mechanism, and its 
relationship to the glucocorticoid-mediated effects described 
above is unknown. The affected component accounts for less 
than 1% of the total histones, and it appears to be lost in a first-
order manner; about 50% remains after 4 hr [49]. 
Summary. A number of factors may contribute to the growth-in-
hibiting effect of glucocorticoids in cultured mouse fibroblasts. As in 
several other cell types, an inhibition of hexose uptake is apparent prior 
to inhibition of nucleic acid synthesis. The mechanisms of inhibition of 
transport and nucleic acid synthesis are not known. The kinetics of 
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inhibition of hexose uptake and nucleic acid synthesis is presented in 
Figure 1. The onset of these inhibitory effects is later, and the time 
course of their development is slower than those observed in lympho, i 
cytes in which the steroid effect is cytolytic [43, 50]. 
Fibroblasts and the Model of Steroid Hormone Action 
Although work on the mechanism of glucocorticoid action 
has not advanced as far as that of sex hormones, there are 
enough observations common to all steroid systems for a general 
model of steroid action to have been developed. In Fig 2, stepS I 
1 through 3 depict the entry of the steroid into the cell, its 
binding to a specific receptor protein located in the cytoplasm, 
and the conversion of the steroid-receptor complex to a form 
(RS") capable of binding to an acceptor site in the nucleus. 
(These events will be considered in subsequent sections of this 
review.) The details of the association of the RS" complex with 
chromatin have not yet been defined, but evidence obtained in \ 
several glucocorticoid-responsive systems is consistent with the 
general hypothesis that nuclear binding of the complex in some 
way causes the production of specific mRNA and the conse-
quent synthesis of new proteins. The physiological effect pro' 
duced by the glucocorticoids depends on the nature of the 
induced proteins and that in turn is a function of the cell type 
being examined, that is, virtually all cells contain glucocorticoid I 
receptors and follow the same pattern of events shown in the 
model, but the types of mRNA that are induced, and conse-
quently the physiological response of the cell, are determined 
by differentiation. 
The most difficult portion of the model to examine with 
respect to the growth-inhibiting action of the glucocorticoids 
may well prove to be the identification of the induced proteins 
that are ultimately responsible for the antianabolic effect. No 
protein (or set of proteins) that could be considered an initiator 
of growth inhibition (or lethal protein in the case of those ceU 
types that are killed) has been identified in any type of glucO-
corticoid-responsive cell. Observations from the laboratories of 
Munck [43] and White [51] suggest the existence of a class of 
glucocorticoid-induced inhibitory proteins in thymic lympho. 
cytes. It has been demonstrated that the inhibition of glucose 
transport occurring in thymocytes 15 to 20 min after exposure 
to glucocorticoid is blocked if actinomycin D is added along 
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FIG 2. Model of glucocorticoid action. After entering the cell (step 
1), the steroid binds (step 2) in a stereospecific, noncovalent manner to 
a soluble protein receptor (R) located in the cytoplasm and thus forrlls 
a steroid-receptor complex (RS) . The complex then undergoes a te!ll' 
perature-dependent transformation (step 3) to a form (RS") capable of 
binding to acceptor sites in the cell nucleus (step 4). The association of 
the RS" complex with chromatin in some way causes the synthesis of 
specific mRNAs (step 5) and consequent new protein synthesis (steP 
6) . The newly synthesized proteins produce the cellular alterations th~t 
mediate the gross physiological effect. In the case of L celis, there 15 
growth inhibition. 
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with the steroid [52], but addition of actinomycin D 5 min after 
addition of cortisol does not prevent the steroid effect. Inhibi-
tors of protein synthesis (cycloheximide and pUl'omycin) block 
the glucocorticoid-mediated decrease in hexose transport if they 
are present from 15 to 30 min after the introduction of the 
steroid but not if they are only present prior to 15 min [43). 
Observations of this type have prompted the suggestion that 
glucocorticoids rapidly induce the transcription of an mRNA 
that in tum di.rects the synthesis of a protein (or proteins) that 
inhibits the transport of glucose into the cell [43,51)' In a similar 
vein, steroid-mediated synthesis of a specific protein may be 
required for the marked decrease in plasminogen activator 
activity observed in L cells exposed to dexamethasone. This 
requirement has not been directly determined in fibroblasts, 
but it may be inferred from the observation that the same 
dexamethasone-mediated decrease in plasminogen activator ac-
tivity observed in cultUl'ed hepatoma cells is blocked by acti-
nomycin D [20). 
Although specific transport-inhibiting or other growth-in-
hibiting proteins have not been identified, there is abundant 
evidence of glucocorticoid-mediated enzyme induction in sev-
eral cell types [1,53] and some evidence for enzyme induction 
in fibroblasts. The level of glutamine synthetase activity rises 
severalfold in L cells exposed to glucocorticoids [54], and the 
increase is blocked by both actinomycin D and cycloheximide 
[55). Alkaline phosphatase activity increases in some cultUl'es 
of skin fibroblasts exposed to glucocorticoids in vitro. This 
phenomenon was not observed in one study [56], but other 
investigators have found significant increases in alkaline phos-
phatase activity in human diploid skin fibroblasts after exposure 
to low concentrations of hormone [57,58). 
In the case of alkaline phosphatase, it has not been estab-
lished that the glucocorticoid-mediated rise of activity in fibro-
blasts is a consequence of new protein synthesis. Induction of 
alkaline phosphatase was carefully examined in a human epi-
thelial cell-line (HeLa 65 cells), and it is clear that in this case 
the increased level of activity was due to an increase in catalytic 
efficiency rather than to an increase in the amount of enzyme 
protein [59). The hormone-mediated rise in enzyme activity in 
HeLa cells was prevented by actinomycin D and cycloheximide 
[59,60], a fact that suggests new protein synthesis is required. 
Alkaline phosphatase is a membrane-associated phosphopro-
tein. It has been pUl'ified from both control and glucocorticoid-
treated HeLa cultUl'es, and the enzyme obtained from the 
treated cells contains approximately one-half the phosphate 
residues associated with the control cell enzyme [61]. Thus, it 
would seem that in this cell type the glucocorticoids either 
induce the synthesis of a protein that alters a protein kinase 
activity or mediate the production of a specific protein phos-
phatase. In any event, a less phosphorylated alkaline phospha-
tase is produced and possibly because of this fact the molecule 
has increased catalytic activity. I have presented this example 
here for 2 reasons: (1) because a similal" mechanism may operate 
in the glucocorticoid-mediated rise in alkaline phosphatase 
activity observed in human skin fibroblasts and (2) to emphasize 
the point that inhibition of a hormone-mediated increase in 
enzyme activity by inhibitors of RNA and protein synthesis 
should not lead one to conclude automatically that the hormone 
has induced the synthesis of that enzyme protein. 
The possibility exists that modifications similar to those 
described for alkaline phosphatase in HeLa cells occw' with 
molecules involved in transport or other cell functions. Perhaps 
then, instead of conceiving that glucocorticoids cause the in-
duction of proteins that specifically inhibit selected biochemical 
processes, one should consider the possibility that they induce 
the synthesis of enzymes that modify proteins involved in key 
processes such as transport. One could hypothesize that the 
glucocorticoid-mediated induction of only a few enzymes ca-
pable of exerting such posttranslational modification of proteins 
could ultimately lead to growth inhibition. Phosphatases are 
reasonable candidates for the proposed induced enzymes be-
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cause their effects could ramify throughout the system, and 
thus perhaps lead to decreased ATP levels, hexose and amino 
acid transport, and nucleic acid synthesis, all of which have 
been observed in cells in which glucocorticoids have a growth-
inhibiting or killing effect. 
The induction of a protein (or set of proteins) is suggested by 
experiments concerned with the effect of glucocorticoids on 
virus replication in fibroblasts. Dexamethasone and other glu-
cocorticoids have been shown to stimulate virus production in 
mouse 3T3 fibroblasts infected with polyoma virus [62]. The 
stimulation of virus production is stereospecific and receptor-
mediated. Also, the production of type-C virus induced by 
5-iodo-2' -deoxYUJ'idine (IUdR) in nonvirus-producing 
BALB/ K3T3 mouse fibroblasts (previously infected with Ku'-
sten murine sarcoma virus [Ki-MuSV)) is stimulated by glu-
cocorticoids [63,64). The steroid alone does not cause vU'us 
production in nonvu'us-producing cells previously infected with 
Ki-MuSV. Rather, it enhances vU'us production in cells already 
induced with IUdR to produce vU'us [64). The step affected by 
the hormone OCCUl'S late in the viral replication cycle, but the 
steroid apparently does not enhance vU'ion assembly or release. 
Pretreatment of induced cells with low concentrations of cor-
dycepin abolishes the dexamethasone stimulation, a fact that 
suggests the steroid-mediated effect comes after the addition of 
poly(A) to vU'al RNA [64). These observations are consistent 
with the proposal that glucocorticoids induce the formation of 
a protein (or proteins) that affects vU'us-specific RNA transla-
tion. Wu et al. have tentatively concluded that the association 
of free virus-specific mRNA with ribosomes or the initiation of 
polypeptide chain synthesis may be enhanced [64). 
Before terminating this discussion of potential gene products 
induced by glucocorticoids in fibroblasts, I should mention the 
negative results obtained in cell hybridization experiments. 
Several laboratories have reported the successful production of 
cell hybrids formed from cultured mouse fibroblasts (either L 
cell or 3T3lines) and rat hepatoma (HTC) cells. Glucocorticoids 
cause the induction of high levels of tyrosine aminotransferase 
activity in HTC cells. The induction process has been studied 
in detail in the hepatoma cells [53], and it is clear that the 
steroid increases the rate of enzyn1e synthesis. Even though it 
could be shown that the hybrid cells contained elements of 
both the rat liver cell and mouse fibroblast genomes, the levels 
of tYTosine aminotransferase were low and the enzyme was not 
inducible by glucocorticoid [65-68]. 
Summary. From observations made in a variety of experimental 
systems, a model of glucocorticoid action has emerged (Fig 2) . The 
essential featUJ"es of the model apply for all of the steroid hormones. A 
critical concept is that the physiological effects of steroid action are 
mediated via the synthesis of specific mRNAs and proteins. The key 
induced proteins that are ult imately responsible for inhibition of fibro-
blast growth have not yet been identified, and their existence can only 
be inferred from indirect observations made in other ceU types. It is 
probable that growth inhibition results from the production of only a 
very small number of proteins. Some of these induced molecules r.lay 
be enzymes that by virtue of their effect on oth er key cellular compo-
nents (protein components of transport systems, etc.) are able to 
compromise multiple systems and produce growth inhibi t ion, The 
pleiotropic nature of glucocorticoid action in general could reflect the 
induction of a very few gene products, some of which are capable of 
exerting a posttranslational modification, 
Interaction of Glucocorticoids with Receptors in Fibroblasts 
A central concept in the model of steroid action is that the 
hormone must bind to a specific receptor protein in order to 
exert its effect on the cell, In the absence of steroid, the receptor 
is located in the cytoplasm. Thus, in contrast to neUl'otransmit-
tel'S and polypeptide hormones, steroids must pass through the 
cell membrane before they can bind to the receptor. Glucocor-
ticoids appru'ently traverse the cell membrane by passive dif-
fusion, and, given the lipophilic nature of these compounds, 
equilibration across membranes is in general very rapid, A 
notable exception to this statement is the passage of glucocor-
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ticoids across the epidermal barrier, where there is considerable 
impedence to penetration. In cultured mouse cell systems we 
have found that the concentration of free steroid achieved in 
the cytoplasm at equilibrium is not necessarily the same as that 
in the growth medium. Mouse fibroblasts (L cells), as well as 
lymphoma (ML-388) and adrenal (Y-1290S3) cells, possess a 
transport system that is capable of transporting some biologi-
cally active glucocorticoids, notably cortisol and dexametha-
sone, from the inside of the cell to the exterior [69,70]. We have 
not found this transport in two varieties of cells cultured from 
human sources (HeLa and WI-38 fibroblasts). The transporta-
bility of a steroid is unrelated to its biological activity. Tiamci-
nolone acetonide and dexamethasone, for example, are both 
biologically active glucocorticoids, but only the latter is trans-
ported. The biological role of the transport system has not been 
defined, but, since it keeps the concentrations of free cortisol 
and dexamethasone in the cytoplasm lower than those in the 
medium, these drugs appear somewhat weaker than they really 
are when their physiological effect in L cells is plotted against 
the concentration of drug added to the culture medium. 
Co-workers and I were able to measure the binding of glu-
cocorticoidsto the ctoplasmic receptor in both intact fibroblasts 
[71] and in high-speed supernatants prepared from hypo-
tonically ruptured cells [72]. The binding of triamcinolone 
acetonide to the L fibroblast receptor is presented in Fig 3 
[73]. In this experiment, we incubated aliquots of a 100,000 xg 
supernatant prepared from L cells with various concentrations 
o(radiolabeled triamcinolone acetonide at O°C for a sufficient 
time to permit the binding reaction to approach completion. 
Other samples of the supernatant were incubated with both 
radiolabeled triamcinolone acetonide and a high concentration 
(2 X 1O-5M) of nonradioactive dexamethasone. Each aliquot 
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FIG 3. Specific binding of radiolabeled triamcinolone acetonide to 
the glucocorticoid receptor in L cell cytosol. Aliquots of a 100,000 Xg 
supernatant from L cells were incubated for 22 hr at O°C with various 
concentrations of ["H) triamcinolone acetonide in the presence (0 ) or 
absence (e) of 5 x 10-& M nonradioactive dexamethasone. The bound 
radioactivity was assayed by passage of each incubation mixture 
through a short column of Sephadex G-25 and by determination of the 
radioactivity associated with the macromolecular fraction. Specific 
binding (_), represented by the dashed line, is the binding achieved in 
the absence of competing steroid (total binding) minus the binding in 
the presence of competitor (nonspecific binding). Inset: a Scatchard 
plot of the binding in the presence of vehicle (data from Pratt, Kaine, 
and Pratt [73]), 
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was then filtered through a small Sephadex G-25 column for 
the purpose of separating the bound from the free drug. The 
assay was based on the principle that the biologically active 
nonradioactive steroid would compete for association with spe-
cific receptor sites and prevent binding of the radio labeled drug. 
No competition should be observed when the radiolabeled drug 
binds nonspecific ally to other proteins in the solution. When 
the nonspecific binding is subtracted from the total binding, the 
difference represents binding to the specific receptor site 
(dashed line). It is evident that specific binding is of a high 
affinity and is saturable. A single set of binding sites is implied 
by the linear nature of the Scatchard plot presented in the 
inset. 
There is considerable evidence that the observed binding 
represents the association of glucocorticoid with its receptor 
site. First, the binding was stereospecific. Only biologically 
active glucocorticoids and glucocorticoid antagonists (e.g., cor-
texolone) competed for the binding of radiolabeled triamcino-
lone acetonide to the fibroblast receptor [71 ,72]. Second, the 
binding affinity of different steroids reflected their physiological 
potency as inhibitors of L cell growth. This fact is shown in Fig 
4, in which dose response curves of growth inhibition (shown at 
the top) are compru'ed to specific binding data for three steroids 
(bottom half) dermined by di.rect assay as in the experiment 
summarized in Fig 3 [73]. Triamcinolone acetonide was the 
most potent of the steroids assayed; dexamethasone was of 
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FIG 4. Comparison of the potency of triamcinolone acetonide, dexa. 
methasone, and cortisol as inhibitors of L cell growth with the ability 
of each steroid to bind to the L cell receptor. The data of the top graph 
(A) are expressed as the percentage of inhibition of L cell growth 
obtained in 5 days of exposure to steroid as compared to inhibition in 
control cultures that grew in the presence of vehicle alone. "Steroid 
concentration" represents the amount of drug added to the culture 
medium. In the lower graph (B) the specific binding of each steroid, 
determined in cytosol preparations as described in Fig 3, is plotted as 
a percentage of the binding at saturation of the receptor versus the free 
concentration of steroid, e, Triamcinolone acetonide; 0, dexametha-
sone; 0, cortisol (data taken from Pratt, Kaine, and Pratt [73]), 
July 1978 
intermediate potency and cortisol was the weakest. The direct 
binding curves are similar to the dose-response data with the 
restriction that the binding curves for cortisol and dexametha-
sone are shifted somewhat to the left of the growth-inhibition 
curves. This shift is probably a consequence of the fact that 
outward transport of these 2 steroids caused their intracellular 
concentrations to be lower than the concentration of drug added 
to the growth medium. Third, the most potent evidence that 
the binding represents association with the receptor site has 
been obtained from studies on resistant fibroblasts; L cells were 
grown in the presence of increasing concentrations of steroid 
until a cell population was obtained that was unresponsive to 
even the most potent glucocorticoids at concentrations a thou-
sandfold higher than those that normally produce maximum 
growth inhibition in the parent line [7l]. These cells were then 
cloned and shown to contain about 10% of the specific binding 
capacity of the sensitive fibroblasts [72]. Because there was no 
change in the affinity of the small amount of binding observed, 
the resistant cells must have lost the ability to bind the drug. 
The binding of the drug to the receptor is presented in Fig 2 
as a single-step bimoleculru' interaction (equation 1, Fig 5); 
however, observations suggest that the binding reaction is more 
complex. From a physicochemical standpoint, the rate of asso-
ciation of glucocorticoids with their receptors was very slow in 
all cell systems examined. In fibroblasts [72] the second order 
rate constants of association at O°C were in the range of 3 to 7 
X 105 M- 1min- l , and an appropriate description of the drug-
receptor interaction must account for this very slow rate of 
binding. Also, an appropriate definition of the binding reaction 
must explain how drugs that bind to glucocorticoid receptors 
can act as agonists, partial agonists, or antagonists depending 
on their chemical structure. Two binding models have been 
advanced to explain these phenomena. In both cases, the as-
sumption was made that the receptor is an allosteric system in 
which the steroid acts as an allosteric effector. 
One proposal (model 2 in Fig 5) assumes that the receptor 
equilibrates between 2 conformational forms, x and y, each of 
which has different activities with respect to enzyme induction 
[74,75]. In this scheme, the x form is the biologically active one. 
According to the model (originally proposed by Rubin and 
Changeux [76]), the behavior of the different classes of steroids 
is explained by their a bility to determine different values of the 
active form as a result of their different affinities for the x and 
y forms. The model predicts that the inactive receptor confor-
R + S ~RS 
Rx + S (agonist) ~ Rx S 
2 L 
Ry + S (antagonist) 
3 
Fast Slow , 
R + S~(RS) ....:: RS 
FIG 5. Equations used to express various models of glucocorticoid 
binding. 1, Single-step interaction. 2, Two conformational state model 
[74]. Receptor equilibrates between 2 conformational forms, x and y. 
Agonists bind to the active form R, and antagonists bind to the inactive 
form Ry produce biologically active and inactive complexes, respec-
tively. 3, Two-step model [73]. Both agonists and antagonists bind 
rapidly to the receptor site, but only agonists can participate in a 
second step in which the steroid-receptor complex is converted to a 
tight binding form, RS'. 
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mation will predominate in the absence of steroid and that fully 
active glucocorticoids will bind principally to the active x form. 
In contrast, pure antagonists will bind only to the y form. The 
model provides an explanation for the slow binding rate as well 
as the agonistic, antagonistic, and partially agonistic effects. 
We have proposed an alternative model consistent with our 
analysis of the kinetics of glucocorticoid binding to L 929 
fibroblast receptors. This model is summru'ized by reaction 3 in 
Fig 5 [73]; the steroid (regru'dless of whether it is an agonist, 
antagonist, or partial agonist) initially binds rapidly to form a 
weak complex with the specific binding site. This binding is too 
weak to be observed with standru"d assay procedures, but the 
weak complex formed with the biologically active steroids is 
slowly converted to the tight form observed in the assay. One 
can conceive that the pme antagonist participates in the initial 
weak interaction but that the antagonist-receptor complex can-
not be converted to the tighter form needed for initiation of the 
physiological response. Partial agonists would produce an effect 
dependent on the proportion of receptor in the tigh t versus 
weak binding state at complete occupancy. Neither binding 
model has been proved true for glucocorticoids, although there 
is adequate precedent for both in other drug-receptor systems. 
I have presented the models here in order to point out that the 
conventional presentation of a sin1ple single-step bimolecular 
interaction (reaction 1) does not explain all of the observations 
made in glucocorticoid binding systems. 
Summary. In order to produce a physiological response, glucocortic 
coids must fust bind to a receptor located in the cytosol fraction of the 
cell. The receptor binds glucocorticoids in a very specific manner. Only 
biologically active glucocorticoids and a few compounds that can act as 
glucocorticoid antagonists (antiglucocorticoids) can bind to the receptor 
site. The binding is reversible,' of high affinity, and satW"able. The 
potency of glucocorticoids as inhibitors of fibroblast growth is directly 
related to the tightness of the binding complex that is formed with the 
receptor [73]. Some L cells that have been selected for glucocorticoid 
resistance contain only 10% of the specific binding capacity of the 
sensitive parent line. Two binding models have been presented (niodels 
2 and 3, Fig 5) that are capable of explaining both the slow rate at 
which glucocorticoids form the binding complex and the fact that some 
steroids can act as pru·tial agonists or antagonists. Two important 
assumptions I have made in considering the steroid receptor interaction 
are that the receptor is an allosteric system and that the steroid acts as 
an allosteric effector. 
Composition and Physical Properties of the L Cell Receptor 
All of the information available regarding the composition 
and properties of the L cell receptor was obtained from studies 
carried out on crude 100,000 Xg supernatant preparations. The 
binding of glucocorticoids was not affected by digestion with 
RNase, lipase, or neuraminidase, but it was eliminated by a 
vru'iety of proteases [71,78]. The steroid-binding ability of the 
100,000 xg prepru'ation was also inactivated by digestion with 
phospholipases A and C [78]. The phospholipase A effect was 
examined in some detail and found to be specific for the action 
of that enzyme. Boiled phospholipase A preparations caused a 
calcium-dependent inactivation of the binding capacity that 
was blocked both by phospholipid and a substrate analogue 
that competitively inhibits the enzyme [78]. One possible ex-
planation for the phospholipase A effect is that the receptor 
protein may be associated in some way with a phospholipid 
component required for specific binding of the hormone. It is 
also possible that the action of phospholipase A on phospholipid 
• We [Pratt and Ishii; 72] had originally thought that the binding of 
triamcinolone acetonide and other potent glucocorticoids to the L cell 
receptor was of the "pseudoirreversible" type observed, for example, 
between methotrexate and fo late reductase at a low pH. This hypoth-
esis clearly is not true, and subsequent studies by Krieger, Middlebrook, 
and Aronow [77J showed that we were misled by salt effects. The rate 
of inactivation of receptor by salt approaches the rate of dissociation; 
therefore, the effect of cold steroid chase, on which these conclusions 
were based was masked. 
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in cytosol preparations results in the production of lysophos-
phatides that inactivate the receptor through a detergent ac-
tion. Other conditions that yield a loss of ability to bind steroid 
include exposure to solutions of high ionic strength [77], sulfhy-
dryl-blocking reagents [79], and low concentrations of deter-
gents of both denaturing and nondenaturing types. 
Association with glucocorticoid markedly stabilized the re-
ceptor against inactivation [72]. Glucocorticoids stabilized the 
receptor roughly in proportion to their binding affinity [80]. 
Because of the lability of the unbound receptor, initial attempts 
at purification focused on use of conventional protein purifica-
tion techniques to concentrate the bound radiolabeled triam-
cinolone acetonide-receptor complex [81]. This complex was 
purified about 2,000-fold, but the product was unstable and the 
ultimate yield was too low for measurement of its physical 
properties. The behavior of the unpurified triamcinolone ace-
tonide-receptor complex was examined by Sephadex chroma-
tography and sucrose gradient centrifugation in hypotonic 
buffer. It was nearly excluded from Sephadex G-200 (consistent 
with an apparent molecular weight of greater than 500,000), but 
the sedimentation coefficient (S20, w5.5) was consistent with 
the value expected for a globular protein with a molecular 
weight of about 85,000. This kind of discrepancy could be due 
to aggregation, association of the drug-receptor complex with 
nonprotein cellular components such as phospholipid, or ex-
treme molecular asymmetry. 
Middlebrook and Aronow (82) recently examined the physi-
cal properties of the drug-receptor complex in detail. It is clear 
from their studies that the physical behavior of the receptor in 
L cell cytosol differs markedly according to the salt concentra-
tion ofthe buffers employed. They determined a partial specific 
volume for the triamcinolone acetonide-receptor complex of 
0.73 to 0.74. This is consistent with a molecule of solely protein 
composition and argues strongly against association of phos-
pholipid with the hormone-receptor complex. Because the ap-
parent size of the complex on Sephadex chromatography and 
sucrose gradient centrifugation varied widely according to the 
ionic strength, calculations of Stokes radii and molecular 
weights also varied widely. From their measurements, Middle-
brook and Aronow concluded that the receptor is a fibrous 
protein with an axial ratio in isotonic buffer of 1:19 oblate or 
1:14 prolate [82]. These values are so large, however, as to seem 
beyond the accuracy of such calculations; they may have been 
considerably distorted by difficulties with aggregation, which 
have been experienced by others who have studied the hepatic 
glucocorticoid receptor [83]. 
Several important observations made by Middlebrook and 
Aronow [82] suggest that there may be different forms of the 
hormone-receptor complex, both before and after association 
with the nucleus. The cytosol steroid-receptor complex was 
found to resolve into 3 peaks on isoelectric focusing (pK 5.8, 
6.4, 6.8). It is possible that these peaks reflect forms of the 
cytosol complex existing before and after transformation to the 
nuclear bindable state. This possibility has been suggested for 
the glucocorticoid receptor in hepatic cytosol [84]. It is also 
possible that, as noted with progesterone-binding molecules, 
there is more than 1 binding protein with the same specificity 
and affinity for glucocorticoids. A thi.rd possibility is that the 
drug-receptor complex associates with other components in 
cytosol that alter its isoelectric point. An important observation 
made in this work is that the triamcinolone acetonide-receptor 
complex isolated by salt extraction of nuclei obtained from cells 
that had been incubated at 37°C with radiolabeled steroid 
(conditions appropriate for transformation and nuclear binding) 
had considerably different physical properties from those of the 
cytosol steroid-receptor complex. The complex obtained from 
nuclei had a much lower apparent molecular weight on Seph-
ad ex G-200 with a Stokes radius of 32A versus 50A for the 
cytosol complex in isotonic salt. The calculated molecular 
weight for the nuclear extractable form of the hormone-receptor 
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complex was 54,000 versus 109,000 for that of the cytosol 
preparation. 
In addition to the steroid-receptor complex that was ex-
tracted into 0.3 M KCI, nuclei from cells incubated with triam-
cinolone acetonide at 37°C contained a significant portion of 
the specifically bound drug in a form that was not extractable 
with salt-containing buffer [85]. This tightly bound form of the 
hormone-receptor complex has been called the nuclear residual 
form, and it can be released from crude chromatin preparations 
with DNase [85]. Although the sedimentation and gel filtration 
properties of this tightly bound complex could not be deter-
mined, it was found to be more stable to thermal inactivation 
than either the cytoplasmic form of the receptor prior to trans-
formation to the nuclear bindable state or transformed receptor 
that was loosely associated with nuclei and extractable with 0.3 
M KCl [82]. 
Summary. The glucocorticoid receptor in L cell cytosol appears to 
be a high-molecular-weight protein, and its physical behavior varies 
markedly according to the salt concentration. The hormone-receptor 
complex is probably very asymmetrical, and free sulfhydryl groups are 
probably required for binding. The determination of a partial specific 
volume of 0.73 to 0.74 is not consistent with the presence of substantial 
amounts of either sugars OJ' phospholipid in the steroid-bound complex. 
The only observation inconsistent with a solely protein composition is 
that the binding activity of cytosol is inactivated by phospholipase 
action, an inconsistency that could be expla ined by detergent effects. 
There is a possibility that more than one physical form of the receptor 
exists in the cytosol. The hormone-receptor complex apparently asso· 
ciates in 2 ways with the nucleus: in a loosely bound, salt-extractable 
state a nd in a tightly bound ("nuclear residual") form that may be in 
close association with DNA. 
The Glucocorticoid R eceptor Cycle 
After hormone binding takes place in the cytoplasm, the 
glucocorticoid-receptor complex is transformed to a form (RS") 
that is then capable of associating with nuclear components 
(step 3, Fig 2). Very little is known about this process in L cells. 
When . intact fibroblasts were incubated with radioisotope-la-
beled glucocorticoid at O°C, most of the bound steroid was 
recovered in the cytosol, but when they were incubated at 37°C, 
there was a shift of the bound radioactivity into the nucleus 
[85]. The mechanism of the temperature-dependent transfor-
mation is not well understood. Studies on the analogous process 
as it occurs with estrogen-binding proteins show that transfor· 
mation in that case is a second order event [86]. The work of 
Middlebrook and Aronow suggests that temperature-dependent 
transformation of the L cell steroid-receptor complex may be 
accompanied by changes in its physical characteristics [82] . In 
any event, the resulting complex became associated with nuclei \ 
where, as described above, 2 association states were evident 
[82,85]. 
No definitive studies on the nature of the nuclear acceptor 
sites have been carried out in fibroblasts. There is some sug-
gestion that there may be a defined number of sites with which 
the RS" complex can interact. Lippman and Thompson (87) 
have shown that L cell cytosol receptor bound with dexameth-\ 
asone and activated under cell-free conditions binds to washed 
L cell nuclei at 20°C. The nuclear binding of the steroid· 
receptor complex under these cell-free conditions is saturable 
at about 2.5 X 10- 9 M. (This concentration represents the 
concentration of specifically bound hormone based on the mo· 
lecular weight of the steroid iteslf.) It is not at all clear, however, 
that the nuclear binding observed under these cell-free condi· 
tions represents a faithful reproduction of the events as they 
occur in intact cells. The results of Lippmann and Thompson 
[68,87] imply that the association has some specificity since 
nuclei appear to bind different glucocorticoid receptors at dif· 
ferent acceptor sites. These investigators found that the L cell 
dexamethasone-receptor complex binds to a satul'able number 
of sites in either fibroblast or HTC cell nuclei. After binding 
the homologus steroid-receptor complex to saturation, either 
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type of nucleus can then bind the heterologous complex, pre-
sumably to a second set of satW'able sites. Lippman and Thomp-
son also suggest that hybrid L/ HTC cells may contain both 
receptors and both classes of nuclear acceptor sites [68]. Again, 
it is not possible to accurately assess the meaning of their 
observations without the assurance that the assay system re-
flects the proper nuclear binding events. 
Some information is available that contributes to OUT concept 
of what may happen to the receptor after it has bound in the 
nucleus. The information was obtained in studies on the energy 
requirement for maintenance of specific binding in the intact 
cell. In the first study that successfully demonstrated glucocor-
ticoid binding to specific receptors, Munck and Brinck-Johnsen 
observed that the amount of binding assayed in intact thymic 
lymphocytes at 37°C was critically dependent on the metabolic 
state of the cell [88]. Specific steroid binding disappeared when 
thymocytes were incubated in glucose-free medium in an at-
mosphere of nitrogen, and it was rapidly restored when the gas 
phase was retW'ned to oxygen. The cells regained their specific 
binding capacity even in the presence of cycloheximide [89]. 
Munck and his co-workers have proposed that the glucocorti-
coid receptor in thymic lymphocytes exists in 2 forms, and that 
energy (ATP?) is required to generate the steroid-binding form 
from a nonbinding precursor [89,90]. 
A similar energy requirement has been found in L 929 fibro-
blasts. When intact L cells were incubated with radiolabeled 
triamcinolone acetonide in glucose-free medium in the presence 
of dinitrophenol, there was a marked loss of specifically bound 
steroid from the cytosol (Fig 6) [91]. When cells were returned 
to a dinitrophenol-free, glucose-containing medium, steroid 
binding returned to control levels, a return that required energy 
and was not affected by inhibitors of protein synthesis. About 
one-third of the dinitrophenol-mediated disappearance of bind-
ing from the cytosol could be accounted for by increased recov-
ery of specifically bound steroid in a low-speed (7,000 xg) 
particulate 'fraction containing the L cell nuclei [91]. A profound 
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FIG 6. Reversible effect of a metabolic inhibitor on specific glucocor-
ticoid binding in the soluble fraction of L cells. A suspension of L cells 
was preincubated for 1 hr at 37°C with radiolabeled triamcinolone 
acetonide. After the preincubation (0 time on the abscissa), the culture 
was split and a portion (e) was incubated in glucose-free medium 
containing 5 X 10-4 M dinitrophenol. After an additional 1.5 hr of 
incubation, the cells were again centrifuged, resuspended, and incu-
bated at 37°C under the following conditions: (0) , glucose-free medium; 
Ca.), glucose-containing medium; (6), glucose-containing medium plus 
puromycin (0.2 mM) . Controls (0 ) were submitted to all procedures, 
but resuspended in glucose-containing medium at 0 time and 1.5 hl". 
[3H]Triamcinolone acetonide was present at 10 nM throughout the 
experiment. Each point represents the specifically bound triamcinolone 
acetonide assayed in a 7,000 xg supernatant prepal"ed from ruptured 
cells. The binding represents both cytoplasmic RS complex and the 
salt-extractable nuclear form (data abstracted from Ishii, Pratt, and 
Aronow [91]) . 
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shift of the steroid receptor complex to the nuclear fraction was 
observed when metabolism was blocked with cyanide instead 
of dinitrophenol [85,91]. After addition of cyanide to a suspen-
sion of L cells equilibrated with radiolabeled triamcinolone 
acetonide, most of the steroid-receptor complex was recovered 
in the tightly bound nuclear form [85]. 
The observations made in fibroblasts appear to be most 
consistent with the existence of 2 energy-dependent steps (Fig 
7) [92]. It seems reasonably clear that the receptor does not 
have to cycle th.rough the nucleus in order for the steroid-
binding form (Ru) to be inactivated to the nonsteroid-binding 
form (Ri ) and for reactivation to occur. This statement is based 
upon 2 facts: (1) inactivation and activation of glucocorticoid-
binding ability occurs in thymocytes incubated under the ap-
propriate conditions in the absence of hormone [89] and (2) we 
have now carried out receptor inactivation and activation in 
isolated cytosol preparations from mouse fibroblasts (Sando 
and Pratt, work in progress). 
The observation that a significant portion of the steroid-
binding capacity of L cells became associated with the nucleus 
when the cell was exposed to metabolic inhibitors is consistent 
with the suggestion [91] that an energy-requiring process is 
required for release of receptor from the nuclear-bound form. 
There is, as yet, no evidence for such an energy-requiring 
release mechanism in other cell types. Sloman and Bell [93] 
carefully examined the effect of dinitrophenol on binding in 
thymic lymphocytes, and they found a reversible loss in cellular. 
binding capacity but they did not observe an increased associ-
ation of the steroid-receptor complex with the nuclear fraction. 
Munck et al. [90], from studies with intact rat thymocytes, and 
Ishii, Pratt, and Aronow [91], on the basis of observations made 
in mouse fibroblasts, have suggested that the recpetor is re-
leased from the nucleus in a form that cannot bind glucocorti-
coids (Ri) . 
Summary. It is clear that cells (thymocytes [88], fibroblasts [91], and 
chick embryo retina cells [94]) require energy in order to bind giuco-
corticoids in a normal manner. From observations made in several cell 
types it has been proposed [85,90-92] that the receptor is cycled 
through different states in the cell. It is possible that a single receptor 
protein may participate several times in the process of steroid binding 
and gene activation. The proposed receptor cycle may play an impor-
tant role in determining the cell 's ability to rapidly change the intensity 
of its physiological response in order to reflect constantly changing 
plasma glucocorticoid levels. The model of the receptor cycle presented 
in Fig 7 is clearly in an early stage of development, but it provides a 
S/RS- >-RS~ 
RO ~\ 
~,lp, nY~ ,i\~ S RS 
ATP "R. ~ /,/ 
I~...... _~ ..... / Chromatin 
--------
CYTOPLASM NUCLEUS 
FIG 7. Proposed cycle of events controlling the binding state and 
cellular location of the glucocorticoid receptor. R i , dephosphorylated 
form of the receptor that is inactive and cannot bind steroid; Ro, 
phosphorylated form of the receptor that binds glucocorticoid in the 
cytoplasm of the cell; RS, steroid-receptor complex; RS", form of the 
steroid-receptor complex that can bind to nuclear acceptor sites; S, 
steroid. Brohen lines refer to processes that appeal' to require energy 
in L cells (taken from Nielsen, Sando, and Pratt [92]). 
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framework on which to ask a number of interesting questions regarding 
the molecular biology of glucocorticoid receptors. 
Glucocorticoid Receptors and Fibroblast Response 
The extent to which a cell can respond to glucocorticoids is 
directly proportional to its ability to bind the dr ugs. If the 
binding capacity of a cell is reduced, the physiological response, 
and consequently the clinical effect, is also reduced . All of the 
information available from both in vivo and in vitro observa-
tions is consistent with the proposal that glucocorticoid-respon-
sive systems obey such an occupancy model. 
There are now several well-studied examples of glucocorti-
coid resistance, and it is clear that in most cases the resistance 
is related to binding capacity. Sibley and Tomkins [95] isolated 
a number of glucocorticoid-resistant sublines of cultured murine 
lymphoma cells and determined the relationship between spe-
cific binding capacity and cell response. About 80% of their 
resistant cell lines were markedly deficient in binding capacity. 
The rest were equally divided between cells with normal cyto-
plasmic binding but with a deficiency in their ability to transfer 
the RS complex to the nucleus, and cells with normal binding 
and transfer that were apparently deficient at some step sub-
sequent to t he nuclear localization of the RS complex. S imilarly, 
in studies on patients with acute lymphoblastic leukemia, a 
direct correlation was demonstrated between clinical response 
to glucocorticoid therapy and the specific binding capacity of 
isolated blast cells [96]. As mentioned previously, the same 
correlation between binding capacity and resistance has been 
demonstrated in L 929 fibroblasts [71 ,72). An increased metab-
olism of steroids h as also been suggested as a resistance m ech-
anism in these cells, but the degree of biotransformation is not 
proportional to resistance and cells also become r esistant to 
synthetic steroids that are not metabolized by this fibroblast 
line [97]. 
There are several ways in which the steroid-binding capacity 
of the cell migh t be altered. There may be a decreased amount 
of receptor protein in the partially responsive or nonresponsive 
cell, and this could result from either a decreased rate of 
receptor synthesis or an increased rate of receptor protein 
degradation. Alternatively, the amount of receptor protein may 
remain constant and the binding capacity may change as a 
result of a decreased rate of receptor activation or an increased 
rate of receptor inactivation. It has generally been assumed 
that a decreased glucocorticoid-binding capacity represents 
either an alteration in receptor affinity or a decrease in the 
amount of receptor protein. In the majority of cases no altera-
tion in affinity has been found, and a decreased receptor protein 
has been assumed. 
In order to better understand the mechanisms that determine 
cellular binding capacity, we examined the process of inactiva-
tion of fibroblast, th ymocyte, and hepatic glucocorticoid r ecep-
tors under cell-free conditions. Unoccupied glucocorticoid re-
ceptors become rapidly inactivated in cell-free preparations. In 
some instances they can be partially stabilized by sulfhydryl-
protecting reagents such as dithiothreitol [98], but in most cases 
the basis for their lability has not been determined. It seemed 
possible to us that the loss of a bility to bind glucocorticoids in 
cell-free systems might reflect the conversion of the receptor to 
a nonsteroid-binding form, as proposed from the observations 
made in intact cells. It is clear from our recent studies that the 
inactivation of glucocorticoid receptors as it occurs in cytosol 
preparations is due to a nonproteolytic enzyma tic action 
[80,99). In rat liver and thymocytes, a considerable amount of 
the inactivating enzyme was located in the 100,000 Xg pellet 
fraction, but there was moderate activity in high-speed super-
natant as well. The distribution of the receptor-inactivating 
enzyme activity in mouse L cells was not determined. The 
receptor-inactivating enzyme was solubilized from the 100,000 
xg thymocyte pellet and partially purified. The solubilized 
enzyme inactivated the glucocorticoid-binding capacity in the 
100,000 Xg supernatant from L fibroblasts, but it had no effect 
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on t he estradiol-binding capacity of a similar preparation from 
rat u terus [80). The enzym es in liver, thymic lymphocytes, a nd 
fibroblasts inactivated unbound glucocortico id receptors but 
they did not cause the release of steroid from the RS complex 
[80,99). The inactivation of specific binding activity in mouse 
fibroblast or rat liver cytosol was inhibited by molybdate, 
fluorid e, and glucose-I -phosphate. The solubilized enzyme from 
rat thymus was inhibited only by glucose-I-phosphate. These 
observations are consistent with the model presented in Fig 7, 
in which it is postulated that the inactivation process is due to I 
dephosphorylation. It has not been shown that the receptor 
protein itself is t he moiety that is dephosphorylated by the 
endogenous inactivating enzymes. 
Additional information supporting the proposal that receptor 
inactivation is a consequence of dephosphorylation was ob-
tained from experiments with purified alkaline phosphatase 
[92). Highly purified alkaline phosphatase from calf intestine \ 
inactivated the glucocorticoid-binding capacity of high -speed 
soluble preparations from rat liver 01' mouse fibroblasts. The 
activity was clearly specific for phosphatase: (1) it was zinc-
dependent, (2) the inactivation was blocked by arsenate, a 
competitive inhibitor of the enzyme, and (3) alkaline phospha-
tase activity and receptor-inactivating activity coeluted on 
DEAE-cellulose purification of the enzyme. The purified phos-
phatase inactivated unbound receptor but did not release ste-
roid from the RS complex. In a mixed preparation containing 
both fibroblast glucocorticoid receptor and uterine estrogen 
receptor, the glucocorticoid-binding capacity was selectively 
inactivated . 
We are just now beginning to investigate the receptor acti-
vation process in cell-free systems. After permitting the specific 
binding capacity of the 100,000 Xg supernatant from rat thy-
mocytes to become inactivated by incubation at 20°C, we are 
able to reactivate it by addition of a factor (or factors) present 
in the high-speed supernatant of mouse fibroblasts (100). We 
do not know how reactivation occurs in this thymocyte system, 
but Granberg a nd Ballard [101] found that a similar reactivation 
by liver cytosol is possibly due to maintenance of sulfhydryl 
groups in the reduced form . In L cells there is some suggestion 
th at reactivation involves a phosphorylation mechanism [100). 
The type of data that suggests the possibility of phosphoryla-
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FIG 8. Inactivation and reactivation of the glucocorticoid-binding 
capacity of fibroblast cytosol. Aliquots of a 100,000 Xg supernatant 
from mouse L cells were incubated at 25°C in the presence (0) or 
absence (e) of 10 mM sodium molybdate, an inhibitor of phosphatase 
action. After 4 hI', either molybdate (0 ) or molybdate and 10 mM ATP 
(A) were added to aliquots of control cytosol and the incubation was 
continued at 25°C. At each time point, samples were removed and 
specific binding capacity was assayed by incubation with ["H]triamcin. 
olone acetonide in the presence and absence of competing dexametha-
sone for 2 hI' at O°C (data taken from Sando and Pra tt, work ill 
progress) . 
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tion is presented in Fig 8. In this case a 100,000 Xg supernatant 
from fibroblasts was incuba ted at 25°C in the presence or 
absence of molybdate, and at various times, aliquots were 
removed and assayed for their ability to bind radiolabeled 
glucocorticoid in a specific tnanner. The receptor activity of the 
control declined, whereas tha t in samples containing the inhib-
itor of phosphatase action remained stable. When further in-
activation of the control was prevented by exposure to molyb-
date at 4 hI', addition of ATP permitted considerable reactiva-
tion of receptor activity. This ATP-dependent event may rep-
resent the same conversion of inactive to active receptor that 
has been proposed for the intact cell. 
Summary. The extent to which a cell can respond to glucocorticoids 
is directly proportional to its a bility to bind the drugs. If the binding 
capacity of the cell is reduced, the physiological response, and conse-
quently the clinical effect , is also reduced. It has been shown that 
glucocorticoid resis tance is most often associa ted with a decrease in (or 
complete loss 00 receptor activity. The receptor activity of a cell could 
be altered either by affecting the am ount of receptor protein or the 
proportion of the receptor that is in the ac tive, steroid-binding state. 
From exper iments demonstrating the energy requirement for ma inte-
nan ce of glucocorticoid receptor activity in intact cells, it has been 
proposed that receptor can be activated by a phosphorylation process 
a nd inactivated by dephosphorylation. Two observations made in cell-
free preparations from fibroblasts and liver support the proposal that 
receptor activity is lost by a dephosphorylation process. First, the 
specific glucocorticoid-binding capacity was inactivated by alka line 
phosphatase. Second, the receptor inactivation caused by endogenous 
enzym es was prevented by inhibitors of phosphatase action. The inac-
tivation that occurred in cell-free preparations through endogenous 
enzyme ac tion is reversible. Further study of the reactions affecting 
receptor activity may lay the foundation for clinical methods of dJ'ug 
treatment that shift greater amounts of receptor to the active fo rm and 
enhance some glucocort icoid effects. 
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The Third Annual Dermatology Seminar at Hawaii sponsored by the University of California, San 
Francisco, Cleveland Clinic and Northwestern University starts the evening of February 12th and ends 
approximately noon February 17, at the Hotel, Intercontinental, Maui, Kehei, Hawaii. The speakers 
include several guests and the faculty of the above departments. Enrollment is limited and made on a 
first come first serve basis. For information write the Department of Dermatology, at either University 
of California Medical School, San Francisco, California 94143, Cleveland Clinic, Cleveland, Ohio, or 
Northwestern University Medical School, Chicago, Ill . 
